Arrowhead (NASDAQ:ARWR) target price lowered to $2.00, issued a report today by Chardan Capital
- Updated: November 29, 2016
Yesterday Arrowhead (NASDAQ:ARWR) traded -1.57% lower at $4.39. The company’s 50-day moving average is $5.64 and its 200-day moving average is $6.10. The last stock close price is down -28.02% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 19,940 shares of the stock were exchanged, down from an average trading volume of 1,021,960
Arrowhead (NASDAQ:ARWR) had its target price lowered to $2.00 by Chardan Capital in a report released 11/30/2016. The new target price indicates a possible downside of -0.54% based on the company's last stock close price.
Previously on 2/10/2016, Jefferies & Co reported about Arrowhead (NASDAQ:ARWR) lowered the target price from $7.00 to $4.00. At the time, this indicated a possible upside of 0.19%.
See Chart Below
Arrowhead has a 52 week low of $3.07 and a 52 week high of $8.22 The company’s market cap is currently $0.
In addition to Chardan Capital reporting its target price, a total of 3 firms have reported on the stock. The consensus target price is $8.92 with 0 firms rating the stock a strong buy, 2 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Arrowhead (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 for providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.